Clinical Trial Update: RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures [Phase 2]

View source ↗

Summary

SPN-817 is being evaluated in a Phase 2 double-blind, placebo-controlled trial in adults with focal onset seizures. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Onset Seizures

Drugs mentioned

• SPN-817 (SPN-817)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Focal Onset Seizures | Phase 2 | Status: RECRUITING